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Treatment for acute myeloid leukemia (AML) has changed little in the past four decades.  
For the majority of AML patients, current treatment options include chemotherapy and 
allogeneic stem cell transplants, which also involves high-dose chemotherapy or radiation 
treatment.  These options have little success in the long-run, as only an estimated 26% of 
patients survive five years post-diagnosis.  In efforts to address this low survival rate, interest 
has increased for targeting epigenetic pathways in AML.  This focus stems from the discovery 
that AML is frequently driven by blockades on hematopoietic stem cell differentiation, which 
involves a series of coordinated epigenetic changes.  Given its reported roles as an epigenetic 
reader, stem cell regulator, and known oncogene, we investigated TRIM24 for putative 
relevance in AML.  Expression data from previous studies have also suggested roles for 
TRIM24 in chronic myeloid leukemia and acute lymphocytic leukemia; however, no studies to 
date have reported measurements of TRIM24 in AML from an in vivo system.  Here, we report 
that low TRIM24 mRNA expression in human AML patients (in TCGA) correlates with poor 
survival.  Additionally, this association was found to be independent of gene expression 
signatures of prognostic significance, such as Gentles leukemic stem cell signature.  
Furthermore, loss of Trim24 in murine, MLL-AF9-driven AML worsened survival and increased 
leukemic stem cell numbers, while having no observed effects on normal hematopoiesis.  These 
results lay the groundwork for future investigations of the role of TRIM24 in AML, which has 
the potential to aid development of novel therapeutic strategies.  
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Introduction & Background: 
Hematopoiesis – an overview: 
Hematopoiesis is the process through which all blood cells are produced.  In humans and 
other mammals, this process takes place primarily within the bone marrow beginning as early as 
embryonic day 15 in mice (1), and month 4 in humans (2). The hematopoietic system’s primary 
responsibilities are conferring immunity and implementing transportation within an organism, 
being the primary entity responsible for the transportation of nutrients, oxygen, hormones, waste 
products, and immune cells.  The broad range of functions required of this system are carried out 
by an array of highly specialized hematopoietic cell types, each differing vastly in morphology 
and function.  Moreover, the constant use of these cell populations leads to a high turnover rate 
of hematopoietic cells, and thus bestows an immense demand for cell production on the 
hematopoietic system, 
producing roughly 1011 
hematopoietic cells daily (3).  
To cope with both the 
demands for cell variety and 
number, the functionally-
disparate cell types which 
comprise the hematopoietic 
system are all produced from 
a single hierarchy of 
differentiation & self-
Figure 1: Overview of the hematopoietic hierarchy 
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renewal (i.e. differentiation cascade), originating from a small group of stem and progenitor cells 
in the bone marrow.   
This hierarchy is headed by hematopoietic stem cells (HSCs), morphologically indistinct, 
immature quiescent cells which have the greatest capacity for self-renewal and the slowest rate of 
division within the hierarchy.  HSCs comprise approximately 1 in 108 nucleated marrow cells 
(non-red blood cells) in human bone marrow (3), dividing once approximately every 40 weeks 
(4).  Categorically, these HSCs are further sub-divided into long-term (LT) and short term (ST) 
HSCs, with ST-HSCs displaying increased rates of division, and LT-HSCs possessing heightened 
quiescence and self-renewal capability (5, 6).  This dichotomy among HSCs adds an additional 
layer to the hierarchy, thus further diluting the burden of replicative stress on the bone marrow.  
These HSCs can divide both symmetrically or asymmetrically to yield multipotent progenitor 
cells (MPPs) (5, 6). MPPs have a lower capacity for self-renewal compared to HSCs, but, 
conversely, have a higher rate of division (5-7). As the name implies, MPPs are capable of further 
differentiating into multiple more specialized progenitor cells, and are more directly responsible 
for meeting the cellular demands imposed on the bone marrow. MPPs differentiate into one of 
many lineage-committed progenitors, which subsequently divide and differentiate into the mature 
effector cells of the hematopoietic system, such as erythrocytes, platelets, granulocytes, 
macrophages, T-cells, B-cells, and NK cells. Granulocytes and macrophages are derived from 
common myeloid progenitors (CMPs), erythrocytes and platelets are derived from 
megakaryocyte-erythrocyte progenitors (MEPs) (which themselves can be derived from CMPs or 
MPPs), and T-cells, natural killer cells, and B-cells are derived from common lymphoid 
progenitors (CLPs).  This extensive hierarchy of self-renewal and differentiation provides an 
elegant system in which all the hematopoietic cell types required by an organism can be produced 
while minimizing divisions within the HSC pool.  While recent evidence suggests this hierarchical 
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system may not be as rigid as previously thought (8-10), this model effectively captures the 
general strategy through which a single human HSC division can lead to the production of over 1 
x 107 hematopoietic cells (4, 11). 
The HSC is the centerpiece of the hematopoietic system, being crucial for maintaining the 
fidelity of all hematopoiesis. As such, the self-renewal, proliferation, and differentiation of HSCs 
are each governed by a multitude of epigenetic and extracellular mechanisms, all of which 
coordinate together as part of the hematopoietic stem cell niche.  More specifically, the HSC niche 
is the culmination of physical and biochemical cues from surrounding adipocytes, nerve cells, 
osteoclasts, osteoblasts, endothelial cells, mesenchymal cells, blood vessels, and sinusoids in the 
bone marrow.  This specialized microenvironment enforces tight regulations on all HSC activities, 
and is partly responsible for preventing malignant expansion of the stem cell pool (12, 13). 
Hematopoietic malignancy: 
 The hematopoietic system is inherently prone to malignancies, as the demand for cell 
production on the hematopoietic system is high in comparison to other tissues (14-17).  The 
hematopoietic system has evolved specific mechanisms to counter this replicative stress, the most 
notable of which are the aforementioned hierarchy and niche.  Additional mechanisms, such as 
regulation by P53 and common apoptotic pathways, help to further counteract effects of the 
immense replicative stress intrinsic to the bone marrow (18-20).  In spite of these mechanisms, 
an estimated 173,000 hematopoietic cancers were diagnosed in 2017 within the United States, in 
addition to 10,000 – 20,000 neoplasms and proliferative disorders such as myelodysplastic 
syndrome (MDS) (21).  Roughly one-third of these cases were leukemia, with 60,000 new cases 
of leukemia diagnosed in the United States each year and a corresponding 24,000 deaths, 
accounting for roughly 4% of all new cancer cases and deaths (21).  Roughly 380,000 people are 
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living with leukemia at any time in the US, with an average 5-year survival rate just over 60% 
(21).   
 Depending on the maturation level of malignant cells, leukemias are generally classified 
as chronic or acute, with acute leukemia having a more severe blockade on cell differentiation, 
and thus a more profound impediment on hematopoietic cell function and patient survival time 
(21).  Both chronic and acute leukemias are further categorized by the cell types the malignancies 
most closely resemble, and are thought to partly reflect the cell type from which the malignancy 
originated (22-24).  The most common types are lymphocytic and myeloid, but mixed lineage 
leukemias are also observed (25-28).  Among these, Acute Myeloid Leukemia (AML) patients 
have an unfavorable prognosis, with a 5-year survival rate of only 26% (21). These also constitute 
roughly a third of all leukemia patients, with approximately 21,000 new cases and 10,500 fatalities 
annually (21).  Acute Myeloid Leukemia (AML), as the name indicates, is an acute leukemia in 
which cells display a myeloid phenotype.  AML is also frequently described as a malignancy of 
the HSC niche, being that this hematological malignancy originates almost exclusively from 
hematopoietic stem and progenitor cells (HSPCs) within the bone marrow (29-31).  Malignant 
transformation of HSPCs gives rise to leukemic initiating cells (LICs), a completely self-renewing 
population of leukemic cells largely agreed to be responsible for driving progression of the disease 
(29-31).  AML can be further sub-divided by utilizing the French-American-British (FAB) 
classification system for AML, which classifies AML cases based on the cell type the malignant 
cells most closely resemble (26).  In this system, the subtypes M0 – M7 correspond with levels 
of cellular maturation, with M0 patients displaying the least differentiated cells, and M4-M7 
patients displaying more mature cell types (26).  This classification system is still broadly used, 
but in recent years has been more frequently used in conjunction with molecular markers, such as 
point mutations and chromosomal abnormalities (32). 
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While 5-year survival for all leukemias has nearly quadrupled since 1960, AML 5-year 
survival rates hover at approximately 26%, as most drugs have proven to be ineffective in the 
long-term (21, 33, 34).  The exception is all-trans retinoic acid (ATRA), approved by the FDA in 
1995 to treat the M3 FAB subtype of AML (34-36).  This subtype of AML, also known as acute 
promyeloitic leukemia (APL), frequently harbors a translocation which results in the expression 
of a PML-RARα fusion protein, halting differentiation in the promyeloitic stage. The APL 
treatment ATRA operates on a concept known as differentiation therapy, which works by forcing 
the self-renewing, immature populations of malignancies to terminally differentiate, hence 
ablating their ability to sustain long-term proliferation and disease.  Specifically for APL, this 
terminal-differentiation is induced by disrupting signaling from the PML-RARα fusion protein, 
thus removing the underlying cause for the differentiation blockade (36).  While the role of ATRA 
is currently limited to the M3 subtype of AML, this treatment is an exemplar for demonstrating 
the feasibility of differentiation therapies, potentially serving as an archetype for future 
treatments.  As such, exploiting differentiation pathways among hematopoietic cells or targeting 
pathways necessary for maintaining pluripotency have become key areas of interest for leukemia 
research. 
Epigenetics in Acute Myeloid Leukemia: 
In accordance with its relevance for the future of differentiation therapy, epigenetics plays 
a central role for the development of acute myeloid leukemia.  This is largely evident from patient 
sequencing data obtained within the past decade, revealing that over 40% of patients do not have 
an identifiable mutation in a signaling gene (such as KRAS or NRAS), and that over 70% of 
patients have at least one non-synonymous mutation in an epigenetic modifier (37).  Moreover, 
these mutations have been frequently identified in genes with global epigenetic influence on the 
genome, such as DNMT3A and TET2 (37).  This information, together with gene expression and 
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amplification data obtained from childhood and adult AML cases, has demonstrated that 
aberrant epigenetic signatures are a universal theme in human leukemia (37, 38).  This 
prevalence supports the notion that epigenetic dysregulation is paramount for the initiation or 
maintenance of hematopoietic malignancies.  The pervasive involvement of epigenetics in AML 
is perhaps best understood when interpreted in the context of what is currently known about 
normal hematopoiesis.  The transition from HSC to mature effector cell is a series of coordinated 
epigenetic changes.  As such, any alteration in an epigenetic pathway could lead to a failed step 
in the differentiation hierarchy.  Any such block on differentiation has the potential to result in 
the eventual development of a hematopoietic malignancy, such as AML. These observations and 
rationale have recently demonstrated utilitarian value in the clinic, as methylation profiling has 
been used to classify subtypes of AML with prognostic significance (39-42).  Similarly, 
methylation profiling has been used to predict the stemness of patients’ AML, with stemness itself 
being negatively associated with survival, and highly informative about a patient’s progression 
and response to treatment (43, 44).  However, this significance appears to not solely be limited to 
epigenetic modifiers.  An increasing amount of evidence suggests that epigenetic readers, proteins 
which interact with epigenetic modifications to enact changes in gene expression or chromatin 
organization, also play a role in leukemic progression (45, 46).  This knowledge extends putative 
relevance in AML to any gene participating in epigenetic pathways, be it through enzymatic or 
merely associative means. 
Fusion genes in Acute Myeloid Leukemia: 
 The importance of epigenetics in leukemia was first recognized through the study of 
chromosomal abnormalities in patients, as clinical observations revealed that recurring 
translocations in leukemia patients produced fusion proteins frequently involving at least one 
epigenetic modifier, such as MLL, MOZ, CBP, P300, or NSD1 (37).  Such chromosomal 
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translocations are common in AML, being present in 30% of non-complex karyotype patients 
(47).  Prognoses vary substantially across patients with each fusion-protein, with patients 
harboring MLL-fusion proteins among the poorest (48-50).  In genetically normal cells, the MLL 
gene (KMT2A) produces an H3K4 methyltransferase tasked with maintaining appropriate 
expression of the HOXA cluster, a collection of genes which positively regulates self-renewal and 
stemness in hematopoietic stem and progenitor cells (HSPCs).  Upon forming a fusion protein, 
the MLL complex co-localizes (by virtue of its nature) with its fusion partner to MLL-target 
locations within the genome, thereby also recruiting complexes the fusion partner may associate 
with.  MLL-fusion leukemia is further subdivided by translocation partner, with over 80 fusion 
partners being described in the literature (51).  The most common fusion partners for MLL in 
AML are AF9, ENL, AF10, ELL, and AF4 (51), all of which are members of the super elongation 
complex (SEC), a large multi-protein complex responsible for exerting global effects on 
transcription (51-54).  In AML, MLL-fusion proteins alter both the recruitment and activity of 
SEC and DOT1L (H3K79 methyltransferase) to enforce aberrantly high HOXA cluster expression 
(52, 55). Consequently, this powerful combination of epigenetic modifications and global changes 
in the transcriptional program in MLL-fusion AML patients leads to a blockade on differentiation 
and malignant transformation of HSPCs. 
Akin to results from ATRA treatment in M3 AML, recent evidence suggests 
differentiation blockades in MLL-fusion leukemia can be circumnavigated (56); however, unlike 
the direct targeting of the PML-RARa fusion in M3 AML, differentiation therapy in MLL-fusion 
AML will likely be enacted through targeting other epigenetic pathways.  For example, epigenetic 
modifiers previously unappreciated in AML, such as protein-arginine methyltransferase 5 
(PRMT5), have been demonstrated to be therapeutically relevant targets for removing the 
differentiation blockade and reducing self-renewal capacity in both mouse models and human cell 
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lines (57). Such discoveries highlight the importance for searching for proteins with epigenetic 
writing or reading ability, and experimentally assaying their potential relevance for MLL-fusion 
AML treatments and differentiation therapies. 
TRIM24 as an Epigenetic Reader and a Regulator of P53: 
TRIM24 is a member of the Tripartite Motif-containing (TRIM) family, a superfamily 
known for E3 ubiquitin ligase activity as well as regulation of autophagy and innate immunity 
(58, 59).  TRIM24 is located on the distal end of the q-arm of chromosome 7 in humans, and 
produces a 1050 amino acid, 117 kDA protein (60).  TRIM24 possesses an RBBCC domain 
towards the N-terminus, consisting of of a RING domain, a B-box, and a coiled-coil.  This domain 
is followed by an LXXLL motif (NR box) starting at amino acid 754, and a PHD and Bromo 
domain at the C-terminus (58-63).  The RING domain of TRIM24 confers the enzymatic function 
of an E3 ubiquitin ligase, and has been demonstrated to directly target p53 for proteasomal 
degradation (61, 62). Furthermore, TRIM24 has also been shown to participate in a negative 
regulatory feedback-loop with p53 in a manner similar to that of MDM2 (61). Meanwhile, the 
PHD domain of TRIM24 has been shown to preferentially bind Histone 3 Lysine 4 in the 
unmethylated state (H3K4me0), while the Bromo domain of TRIM24 has been demonstrated to 
preferentially associate with Histone 3 Lysine 23 in the acetylated state (H3K23ac)(63). Via 
histone peptide arrays, the simultaneous binding of both histone marks has been demonstrated to 
be critical for the independent association (i.e. in the absence of other proteins) of TRIM24 with 
chromatin (63).  This association has been demonstrated to only be favorable in the cis-
conformation, as other arrangements have poor binding kinetics (63).  The simultaneous presence 
of both of these chromatin marks represents a non-canonical histone signature, the roles of which 
have yet to be fully investigated (63). 
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Originally known as Transcription Intermediary Factor 1 Alpha (Tif1α), the first study on 
Trim24 was published in 1995, which reported Trim24 as a component of the mouse 
hepatocellular carcinoma fusion oncoprotein, T18 (64, 65).  At the time of this study, TRIM24’s 
known roles were limited to interactions with nuclear receptors and enhancement of retinoic acid 
receptor signaling (65).  While informative, TRIM24 research remained little beyond the scope of 
nuclear receptor signaling until the Barton lab demonstrated its role as a p53-targeting E3 
ubiquitin ligase in 2009 (66).  Knowledge of TRIM24 has since expanded drastically, with 
demonstrated roles in Wnt, PI3K/Akt, and STAT signaling, as well as in innate immunity, 
pluripotency, and embryonic stem cell transcription (67-74). Through manipulating these 
pathways, overexpression of TRIM24 has been demonstrated to influence a wide variety of human 
malignancies, including breast cancer, head & neck cancer, glioblastoma, non-small-cell lung 
cancer, prostate cancer, cervical cancer, and hepatocellular carcinoma (63, 70, 75-81).  In the case 
of hepatocellular carcinoma, both overexpression and deletion of TRIM24 lead to malignancy (78, 
79).  This indicates that the role for TRIM24 may not be as simple as that of a typical oncogene, 
but may rather be part of a balancing act in preventing oncogenesis, requiring regulation in a 
precise, context-dependent manner.  This balancing act may hold relevance for so far 
uninvestigated malignancies with respect to TRIM24, the prospect of which warrants further 
investigation. 
Rationale – TRIM24’s Putative Role in AML: 
The functional abilities of TRIM24, and the pathways they regulate, make the gene an 
interesting candidate for examining its therapeutic relevance in AML.  Accordingly, TRIM24 has 
recently been within the focus of gene expression studies conducted on both ALL and CML 
samples (82, 83).  In CML, TRIM24 expression was elevated in the late stages of CML, suggesting 
it may play a role in the transition to blast crisis, the most advanced form of the disease (83).  
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Conversely, in ALL, TRIM24 mRNA 
expression was associated with favorable 
patient status, as patients expressing higher 
levels of TRIM24 mRNA displayed a lower 
percentage of blast cells (undifferentiated 
cells) 28 days post-diagnosis (82).  In both 
cases, the data suggests that TRIM24 may 
affect pathways central to the malignant 
hematopoietic state.  As is the case with 
hepatocellular carcinoma, the above data 
suggests that TRIM24 may play a balancing 
act in leukemia, potentially exhibiting 
varied, context-dependent effects on 
hematopoietic malignancies.  If and how this may relate to Trim24 in AML has yet to be 
determined. As acute leukemias generally share more similarities than they do with chronic 
leukemias, TRIM24 is more likely to affect AML in a manner similar to how it affects ALL, than 
CML.  To this end, a review of the literature revealed that the genomic location of TRIM24 
(chromosome 7q) is deleted in roughly 10% of both AML and MDS patients, and is associated 
with a poor prognosis in both instances (84, 85).  An additional search among data available in 
The Cancer Genome Atlas (TCGA) AML dataset revealed that patients above mean TRIM24 
mRNA expression survived roughly 1.8 times longer than patients below mean TRIM24 mRNA 
expression (p-value 0.0003) (figure 2).    
These combined data have led us to hypothesize that loss of TRIM24 promotes the 
progression & aggressiveness of AML.  Moreover, AML is characterized by the aberrant 
Figure 2: TRIM24 mRNA correlates with human survival
Y-axis represents percent of surviving patients while x-axis 
represents months of patient survival post-diagnosis.  
TRIM24 high expressing patients (red) and TRIM24 low 
expressing patients (blue) were separated into their 
respective groups based on their TRIM24 expression in 
comparison to the mean TRIM24 expression of the group.  
All data in this figure was obtained from TCGA. 
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expression of genes crucial for hematopoietic development & maintenance.  This, coupled with 
the demonstrated roles for TRIM24 in regulating embryonic stem cell expression & pluripotency, 
has led us to also hypothesize that TRIM24 plays an important role in normal hematopoiesis.   
To address these hypotheses, we aim to characterize the role of TRIM24 in acute myeloid 
leukemia, and define its role in normal hematopoiesis (detailed in figure 3). 
 
 
 
 
 
 
 
 
Figure 3:  Aims of study 
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Results: 
Colony formation: 
In order to gauge the self-renewal 
capacity of MLL-AF9 transformed leukemic 
bone marrow for both Trim24 wildtype and 
Trim24 knockout cells, colony formation 
assays were performed in a semisolid medium 
supplemented with cytokines. For passage 1, 
the colony formation assays (n=3) yielded an 
average of 151.7 ± 42.4 colonies for Trim24 
knockout cells and 60.7 ± 20.2 colonies for 
wildtype cells. The difference between these 
two groups is 91 colonies, with a p-value of 
0.12.  For passage 2, the Trim24 knockouts averaged 166.7 ± 46.8 colonies, and the wildtypes 
averaged 66.7 ± 22.1 colonies, with a difference of 100 between the two groups and a p-value of 
0.13. For passage 3, the Trim24 knockouts averaged 183.3 ± 63.5 colonies, and the wildtypes 
averaged 68.6 ± 36.7 colonies, with a 114.7 difference between the two groups, and a p-value of 
0.19.   
  
Figure 4:  Trim24 knockout cells have increased 
colony formation ability
 
The y-axis represents total colony count per passage, 
while the x-axis contains the categories for Trim24 
wildtype (red), and Trim24 knockout (blue), for each 
passage of cells in the experiment (3 in total). 
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Cell counts: 
 In order to gauge for potential effects on 
proliferation, cell counts were performed on 
several passages of Trim24 wildtype and Trim24 
knockout cells in semisolid media (n=3).  Trim24 
wildtype cells produced an average of 2.5 ± 0.5 x 
106 cells per passage, whereas Trim24 knockout 
cells produced an average of 3.56 ± 0.1 x 106 cells 
per passage.  This yields a roughly 1.1 x 106 
difference between the two groups, approaching 
significance with a resulting p-value of 0.0634. 
Giemsa stains: 
 Giemsa stains aid in the visualization of 
morphological differences between hematopoietic 
cell types by not only making cellular features such 
as the nucleus more distinct, but by also providing 
unique staining patterns for specific cell types (such 
as light pink stain for erythroid cells).  This staining 
provides the stark visual differences needed to 
manually distinguish between hematopoietic cell 
types, and enables manual enumeration of major 
hematopoietic cell populations.  As such, this is 
frequently used as a method to measure blast counts 
Figure 5: Trim24 knockout cells have 
increased cell number in vitro
 
The y-axis represents total cell number per 
passage.  The x-axis contains the categories for 
the control group (Trim24 WT), and Trim24 
knockout (-/-). 
Figure 6:  Trim24 knockout cells show no 
difference in blast percentage
 
The y-axis represents the percentage of blast 
cells out of total cells enumerated via Giemsa 
staining.  The x-axis represents the categories of 
Trim24 knockout (blue) and Trim24 wildtype 
(red) for both in vivo and in vitro experiments. 
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and biases towards the maturation of specific hematopoietic lineages.  After performing Giemsa 
stains on in vitro generated Trim24 knockout and wildtype AML, we measured no significant 
difference in blast counts, with the knockout group displaying a blast percentage of 79, and the 
wild-type group a percentage of 81.7, with a 0.85 p-value between the two groups.  Additionally, 
a similar result was observed in subsequent in vivo assays, with the knockout group displayed a 
blast percentage of 26.3, and wild-type group a percentage of 31.3, with a 0.7 p-value between 
the two groups. 
Primary transplant: 
 For better understanding the potential 
role Trim24 may play in in vivo survival, we 
injected mice with Trim24 knockout and 
wildtype leukemic cells generated in vitro, in 
an assay known as a primary leukemic 
transplant.  The primary transplant revealed 
that mice with Trim24 wildtype leukemia 
succumbed to the disease after an average of 
49 days, whereas the mice with Trim24 
knockout leukemia succumbed after an 
average 70.5 days, with 50% censored at day 
80.  This yields a 21.5 day difference 
between the two groups, approaching statistical significance with a p-value of 0.0814.  Two 
repeats of the primary transplant have so far failed to engraft. 
  
Figure 7: Mice with Trim24 knockout primary AML 
trend toward survival disadvantage
 
The y-axis represents the percentage of surviving 
patients in each group, while the x-axis represents the 
time of survival for mice after being injected with 
leukemic cells.  Trim24 knokcout group is represented in 
blue, whereas the Trim24 wildtype group is represented 
in red. 
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Secondary transplant: 
We next performed what is known as a 
secondary leukemic transplant by 
harvesting leukemic bone marrow cells 
from deceased mice in the primary 
transplant, and subsequently re-injecting 
them into immunocompromised mice.  The 
purpose of such serial transplantations is to 
reveal long-term differences in the ability 
of a genotype to maintain a leukemic 
initiating cell (LIC) population, as such 
differences in self-renewal capacity are not 
always readily observable in primary 
transplants.  The secondary transplants 
revealed a stark difference in the survival 
times between mice with Trim24 wildtype 
leukemia and mice with Trim24 knockout 
leukemia, with the knockout group 
displaying an average survival of 30.8 
days, and the wildtype group displaying an 
average survival of 66.8 days, with 4 out of 
6 censored at day 80.  This gives a 36 day difference between the survival of the two groups, 
reaching statistical significance with a p-value of 0.0012.  The secondary transplant was repeated, 
with the knockout group displaying an average survival of 45 days, and the wildtype group 
Figure 8:  Mice with Trim24 knockout secondary 
AML show strong survival disadvantage.
 
For both figure 8 a) and figure 8 b) the y-axis represents 
the percentage of surviving patients in each group, while 
the x-axis represents the time of survival for mice after 
being injected with leukemic cells.  Trim24 knokcout 
group is represented in blue, whereas the Trim24 
wildtype group is represented in red.  Figure 8 a) 
represents the first iteration of the secondary transplant, 
whereas figure 8 b) represents a repeat. 
a) 
b) 
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displaying an average survival of 100 days, with 5 out of 6 censored at day 100.  This gives a 55 
day difference between the survival of the two groups, reaching statistical significance with a p-
value of 0.0017.  
Leukemic initiating cells:    
To enumerate the rare cell population within 
leukemic tissue known as leukemic initiating 
cells (LICs), we performed antibody-staining 
and flow cytometry analysis on Trim24 
knockout and wildtype leukemic bone marrow 
from the transplantation experiments. The flow 
analysis revealed that mice with Trim24 
knockout leukemia have approximately six 
times as many leukemic initiating cells (GFP +, 
Sca1 -, lineage low, C-kit +, CD34 +, FcyR III/II 
-), with the knockout group having an average of 
approximately 870,000 leukemic initiating cells, and the wildtype group having an average of 
approximately 142,000 leukemic initiating cells.  The exact difference is statistically significant, 
reaching a p-value of 0.0247.  
  
Figure 9: Mice with Trim24 knockout AML 
show 6-fold increase in leukemic initiating cells  
The y-axis represents the total number of leukemic 
initiating cells (LICs) enumerated per sample, 
while the x-axis contains the categories of Trim24 
wildtype leukemia (control) and Trim24 knockout 
leukemia (Trim24 -/-). 
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HOXA cluster expression: 
 To determine if altered HOXA cluster 
expression, a hallmark of MLL-fusion AML, 
varied between Trim24 knockout and wildtype 
leukemic mice, we isolated RNA from our 
leukemic tissue, and performed qPCR.  Analysis 
of the qPCR data revealed no significant 
difference in the expression of HOXA9, with 
Trim24 knockout leukemic cells expressing 0.9 
the amount of wildtype cells, with a non-
significant p-value of 0.21.  Additionally no 
significant difference in the expression of 
MEIS1 (canonically expressed with the HOXA9 
cluster) was detected either, with Trim24 
knockout leukemic cells expressing 1.06-fold 
more than wildtype cells, with a non-significant 
p-value of 0.24.  
Prognositc indicators: 
To gather a more complete understanding of the 
putative clinical relevance of TRIM24, we first examined TRIM24 mRNA expression in the 
context of patient prognostic markers.  As can be seen in (figure 11 a), based on cytogenetic 
prognostic markers, TRIM24 mRNA expression correlated with a favorable prognosis, with 
patients in the “Good” group expressing an average of 2784 reads per kilobase million (RPKM), 
Figure 10:  Mice with Trim24 knockout AML 
show no difference in HOXA cluster expression. 
In 
both figure 10 a) and figure 10 b), the y-axis 
represents mRNA expression normalized to the 
control group (Trim24 wildtype), while the x-axis 
contains the categories “Control” and “Trim24 
knockout”.  Figure 10 a) contains data for 
expression of HOXA9, while figure 10 b) contains 
data for expression of MEIS1. 
a) 
b) 
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while patients in the “Intermediate” and “Poor” 
groups expressing an average of 1918 and 1703 
RPKM of TRIM24 mRNA respectively.  After 
performing an ANOVA, the resulting p-value 
was less than 0.0001 in both cases when 
comparing “Good” to “Intermediate” or 
“Poor”.  No statistically significant difference 
was observed when comparing the 
“Intermediate” or “Poor” groups.  Additionally, 
to determine if the observed association with a 
favorable prognosis could be attributed to 
altered mutation frequency, we next compared 
mutation rate with TRIM24 mRNA expression 
per patient. Shown in (figure 11 b), TRIM24 
mRNA did not correlate with mutation rate in 
the TCGA AML dataset.  Linear regression 
analysis resulted in a slope of 19.47, less than 
1% of the mean TRIM24 mRNA expression, 
and was not statistically significant, with a p-
value of 0.115.  The R-value (correlation coefficient) of the regression line generated was 0.015. 
 
 
 
Figure 11: TRIM24 mRNA correlates with 
favorable prognostic markers, independent of 
mutation rate.
 
In figure 11 a) the y-axis represents TRIM24 
mRNA expression in reads per kilobase million 
(RPKM), while the x-axis contains three prognostic 
categories.  In figure 11 b) the y-axis represents 
TRIM24 mRNA expression in RPKM, while the x-
axis represents total exome mutations per patient.  
All data in both figures were obtained from TCGA. 
b) 
a) 
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TRIM24 mRNA expression by AML subtype: 
To assess the potential for 
subtype-specific biases of TRIM24 
expression, we examined the 
relationship between TRIM24 
expression and FAB subtype.  As 
shown in (figure 12), the M3 FAB 
subtype displayed the highest mean 
TRIM24 mRNA expression with an 
average of 2709 RPKM, reaching 
statistical significance when 
compared to M1, M4, and M5.  
Additionally, the M5 subtype 
displayed the lowest mean TRIM24 
mRNA expression with an average of 1173 RPKM, reaching statistical significance when 
compared to M0, M1, M2, and M3.  
Figure 12: TRIM24 mRNA expression varies across 
distinct AML subtypes
 
The y-axis represents TRIM24 mRNA expression in RPKM, 
while the x-axis contains categories containing the six most-
frequent subtypes of AML, according to the French-American-
British (FAB) classification system. 
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TRIM24 mRNA in HSCs & AML subtypes: 
As changes between hematopoietic stem 
cells (HSCs) and leukemic cells can be indicative 
of alterations beneficial to leukemic progression, 
we next examined TRIM24 expression among five 
AML types and compared the mean expression of 
each group to that of HSCs.  The data utilized for 
this analysis was obtained from the BloodSpot 
database.  The BloodSpot database executes a 
batch-correction protocol on microarray data from 
various studies in order to make them comparable, 
enabling the comparison of leukemic data from the 
MILES study to hematopoietic data obtained from 
individual researchers.  As can be seen in (figure 
13), TRIM24 expression is reduced among all five AML subtypes when compared to HSCs, all 
reaching statistical significance, each with a p-value less than 0.0001. 
TCGA patient survival: 
To further evaluate TRIM24’s potential clinical relevance, we next examined survival 
trends between patients above mean TRIM24 mRNA expression, and patients below mean 
TRIM24 mRNA expression.  As can be seen in (figure 14 a), patients with above mean TRIM24 
mRNA expression survived an average of 35.6 months, whereas patients below mean TRIM24 
mRNA expression survived an average of 19.6 months.  The survival difference between these 
two groups is significant, reaching a p-value of 0.0003. 
Figure 13:  TRIM24 mRNA is reduced in AML 
subtypes when compared to HSCs.
 
The y-axis represents TRIM24 mRNA expression 
in RPKM, while the x-axis contains categories of 
five AML subtypes, and one category for 
hematopoietic stem cells (HSC).  All data in this 
figure was obtained from the BloodSpot database. 
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As can be seen in (figure 12), 
TRIM24 expression correlated with the M3 
FAB subtype of AML, which has a strongly 
favorable prognosis in comparison to the 
other FAB subtypes.  To understand to what 
extent this association could be affecting 
the observed survival trend, we performed 
a separate survival analysis excluding all 
M3 patients (16 total).  The resulting 
analysis (figure 14 b) shows that excluding 
M3 patients did not substantially affect 
survival, with a resulting p-value still 
significant at 0.0057.  To further scrutinize 
the relationship between TRIM24 mRNA 
expression and survival, our bionformatics 
collaborator (Yi Zhong) performed an 
independent survival analysis (figure 15) by 
removing arbitrary cut-offs such as “the 
mean”, and instead used an optimized 
cutoff to define TRIM24 high and low-
expressing groups (see methods).  This 
survival analysis was congruent with the prior two analyses, with TRIM24 high expressing 
patients surviving longer than TRIM24 low expressing patients, with a p-value of .0007. 
  
Figure 14:  TRIM24 mRNA correlates with human 
survival across subtypes.
The y-axis represents percent of surviving patients while 
the x-axis represents months of patient survival post-
diagnosis.  TRIM24 high expressing patients (red) and 
TRIM24 low expressing patients (blue) were separated into 
their respective groups based on their TRIM24 expression 
in comparison to the mean TRIM24 expression of the 
group.  All data was obtained from TCGA.  Figure 14 a) 
and figure 14 b) differ only in that patients of the M3 
subtype (16 in total) were excluded from the analysis in 
figure 14 b). 
a) 
b) 
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Figure 15:  Trim24 mRNA correlates with 
survival in independent, optimized-cutoff, 
ranked survival analysis.       
The y-axis represents the proportion of surviving 
patients in comparison to the total patients 
surviving (with 100% surviving represented by 1).  
The x-axis represents days survived post-diagnosis.  
TRIM24 high expressing patients (red) and 
TRIM24 low expressing patients (green) were 
defined by an optimzed cut-off algorithm.  All data 
analyzed was obtained through TCGA.  This figure 
is the reuslt of a collaboration with Yi Zhong. 
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TCGA Patient characteristics:  
To determine if patient cell type biases were observed on the basis of TRIM24 expression, 
we next examined TRIM24 expression per patient in the context of various patient hematopoietic 
cell types.  Demonstrated in (figure 16), TRIM24 expression did not reaveal any statistically 
significant correlation with peripheral blood blast percentage (p-value 0.32), white blood cell 
count (p-value 0.11), basophil count (p-value 0.93), abnormal lymphocyte count (p-value 0.13), 
nor platet count (p-value 0.43).  TRIM24 did demonstrate a stastistically significant linear 
relationship with bone marrow blast percentage (p-value 0.02); however, the R-value (correlation 
coefficient) obtained from the linear regression analysis was 0.033, indicating an extremely weak 
linear relationship.  The resulting slope (-8.3) is less than 0.41 % of the mean TRIM24 mRNA 
expression. 
Figure 16:  TRIM24 mRNA does not correlate with enumerated patient cell types. 
 
For figures 16 a) through figure 16 f), the y-axis represents TRIM24 mRNA expression in RPKM while the x-
axis represents numbers of white blood cells (WBC), basophil count, bone marrow blast percentage, 
abnormal lymphocyte percentage, platlet count, and peripheral blood blast percentage, respectively.  All data 
in this figure was obtained through TCGA.  The black line in each figure represents the slope generated from 
linear regression analysis. 
a)  b)  c) 
d)  e)  f) 
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TCGA HOXA cluster expression: 
As with our in vitro and in vivo mouse 
AML samples, we next measured the co-
expression between TRIM24 and HOXA9, and 
TRIM24 and MEIS1 among all TCGA AML 
patients with mRNA sequencing data available.  
Statistically significant relationships were 
observed in both instances, with p-values of 
less than 0.0001; however, the associations 
were weak, with HOXA9 co-expression 
yielding an R-value of 0.13, and MEIS1 
expression an R-value of 0.09.  Repeating the 
analysis by examining TRIM24 mRNA rank in 
comparison to HOXA9 or MEIS1 expression 
rank yielded a similar result, with R-values of 
0.16 and 0.15 respectively. 
  
Figure 17:  TRIM24 shows only weak association 
with HOXA cluster expression in TCGA. 
 
In both figure 17 a) and figure 17 b) the y-axis 
represents TRIM24 mRNA expression in RPKM, 
while in 16 a) the x-axis represents MEIS1 expression 
in RPKM, and in 16 b) the x-axis represents HOXA9 
expression in RPKM.  The black line in each figure 
represents the slope generated from linear regression 
analysis. 
a) 
b) 
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Pathway Enrichment: 
As the major gene cluster which facilitates LIC expansion in MLL-fusion AML was not 
strongly associated with TRIM24 expression, we decided to next perform gene enrichment 
analysis on the co-expression data available from TCGA.  Through collaboration with Yi Zhong, 
we obtained over 600 pathways significantly associated with TRIM24 expression; however, many 
of these pathways encompassed various pathways involved in immune cell functions.  As such, 
in table 1, we chose show the enrichment of 7 broad pathways which encompass many of the 
other pathways enriched in the TRIM24 co-expression data.  Additionally, at the bottom of table 
1, we show the non-significant p-value for the association of a leukemic stem cell signature 
accepted for its prognostic value.  This lack of an association with the canonical leukemic stem 
cell signature suggests a non-canonical survival mechanism may be responsible for TRIM24’s 
associations with survival (see discussion). 
 
Table 1:  Summarized pathway enrichment analysis
 
The leftmost column displays the names for gene expression signatures from the Gene Ontology (GO) 
database.  The middle column represents the p-value associated with their enrichment based on TRIM24 
mRNA expression, while the rightmost column displays nature of the association (i.e. positive vs. 
negative correlation).  The first seven pathways listed represent pathways of interest for their statistically-
significant associations with TRIM24 mRNA, whereas the eighth pathway listed is a pathways with 
prognostic significance, noted in the literature for its association with leukemic stem cells. 
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Each of the pathways in 
Table 1 were evaluated for its 
correlation with survival in TCGA 
AML patients.  Among these, 
leukocyte activation strongly 
associated with survival with a p-
value of 0.0067 when comparing 
patients above and below median 
expression for the signature (figure 
18).  
To determine if TRIM24’s 
negative association with the more 
mature M4 and M5 FAB subtypes 
(seen in figure 12) could account for 
TRIM24’s negative association with 
the leukocyte activation signature, 
we measured the co-expression of TRIM24 with the “leukocyte activation” signature among solely 
M4 and M5 subtypes (excluding M0-M3 patients).  Similar pathways, including the leukocyte 
activation signature, were still enriched among M4 and M5 patients. 
 
  
Figure 18:  Leukoctye activation signature negatively 
correlates with human survival.
 
The y-axis represents percent of surviving patients while the x-
axis represents days of patient survival post-diagnosis.  
Leukocyte activation high-expressing patients (red) and 
leukocyte activation low-expressing patients (blue) were 
separated into their respective groups based on their TRIM24 
expression in comparison to the median leukocyte activation 
expression of the group.  All data in this figure was obtained 
from TCGA, and analyzed through software available through 
the BloodSpot database. 
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Mutation enrichment by TRIM24 mRNA expression: 
To determine if 
differences in 
mutation patterns 
existed between 
TRIM24 high and 
low expressing 
groups in TCGA, 
we compared the 
frequency of 
mutations for the 
top 12 most 
frequently mutated 
genes in AML 
between both 
groups.  Defining high and low TRIM24 expression based on the mean, or based on TRIM24 
expression greater or less than 1 standard deviation from the mean both yielded the same 
associative patterns between TRIM24 mRNA expression and mutation frequency among the 12 
genes (results in table 2). 
 
 
 
 
Table 2: Enrichment of common mutations based on TRIM24 mRNA expression 
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TRIM24 mRNA expression in non-AML TCGA datasets: 
 In order to gather a more 
complete understanding of the biology 
behind loss of TRIM24 expression in 
AML, we sought to find examples of loss 
of TRIM24 correlating with poorer 
survival in other human malignancies.  
To this end, we analyzed survival based 
on TRIM24 expression among all TCGA 
datasets possessing mRNA sequencing.  
From the data available, reduced 
TRIM24 mRNA expression correlated 
with poorer survival in TCGA thyoma 
patients. Shown in (figure 19), patients 
below mean TRIM24 mRNA expression 
displayed poorer survival when compared to patients above mean TRIM24 mRNA expression, 
with a p-value of 0.0215 when comparing the two groups. 
To gather an understanding of the pathways putatively responsible for this survival 
relationship, we performed a gene enrichment analysis among TRIM24 co-expressed genes in 
TCGA thyoma patients.  Similar pathways to those enriched among the AML patients, including 
the leukocyte activation signature (p-value 0.00943), were enriched among genes negatively 
associated with TRIM24 expression in thyoma patients. 
  
Figure 19:  TRIM24 mRNA expression correlates with 
survival in human thyoma patients
 
The y-axis represents percent of surviving patients while the 
x-axis represents months of patient survival post-diagnosis.  
TRIM24 high expressing patients (red) and TRIM24 low 
expressing patients (blue) were separated into their 
respective groups based on their TRIM24 expression in 
comparison to the mean TRIM24 expression of the group.  
All data was obtained from the thyoma dataset in TCGA. 
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TRIM24 Expression by Cell Type: 
To first gain an understanding of how 
TRIM24 could putatively affect hematopoiesis, 
we examined TRIM24 mRNA expression by each 
major cell type in the hematopoietic 
differentiation hierarchy. This was accomplished 
by once again utilizing the batch-corrected data 
from the BloodSpot database. Demonstrated in 
figure 20, TRIM24 mRNA is highest among 
HSCs, and decreases with increasing levels of 
cell maturation, with (BC, PMN, and MONO) 
displaying the lowest levels of TRIM24 
expression. 
  
Figure 20: TRIM24 mRNA expression is 
decreased in mature hematopoietic cell types. 
Figure 20 demonstrates that TRIM24 mRNA 
expression is highest in hematopoietic stem cells 
(HSC) and lowest in differentiated cell types such 
as monocyte (Mono) and granulocytes (PMN).  
The y-axis demonstrates batch-corrected TRIM24 
mRNA expression values, while the x-axis 
contains all categories (cell types) examined.  All 
batch-corrected mRNA exmamined in this figure 
was obtained from the BloodSpot database. 
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In an effort the role Trim24 may play on 
major hematopoietic cell populations, we 
enumerated lymphocyte, neutrophil, and 
monocyte populations by utilizing side-scatter 
and forward-scatter metrics from flow 
cytometry experiments (see methods).  As 
demonstrated in figure 21, in both Trim24 
knockout cells from the bone marrow and 
spleen, no difference in cell number was 
observed. 
  
Figure 21: No difference in major cell 
populations between Trim24 knockout and 
Trim24 wildtype tissue. 
 
Both figures 21 a) and 21 b), no difference in 
major cell populations were detected between 
Trim24 wildtype and knockout groups. In both 
figure 21 a) (bone marrow) and figure 21 b) 
(spleen) the y-axis represents the percentage of 
cells harvested from the tissue examined.  In both 
figures, the x-axis contains the categories 
measured in each experiment, which are Trim24 
knockout (Trim24 -/-) and Trim24 wildtype 
(Trim24 WT) groups for neutrophil, monocyte, 
and lymphocyte measurements.  In figure 21 b), 
neutrophil and monocyte counts were 
unmeasurably low. 
b) 
a) 
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HOXA cluster expression in healthy bone marrow: 
As with the leukemic bone marrow, 
we also used HOXA9 and MEIS1 qPCR 
primers to gauge levels of HOX cluster 
expression.  As shown in figure 22, no 
difference in HOX cluster expression was 
indicated by our qPCR. 
  
Figure 22: No difference in HOXA cluster 
expression between Trim24 knockout and 
Trim24 wildtype healthy bone marrow
 
Figure 22 demonstrates no distinguishable 
difference in major HOXA cluster genes was 
observed between Trim24 knockout and Trim24 
wildtype healthy bone marrow.  the y-axis 
represents mRNA expression normalized to the 
control group (Trim24 wildtype), while the x-axis 
contains the categories “Control”, “Trim24 
knockout (-/-) HOXA9” and “Trim24 knockout (-/-
) MEIS1. 
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Effect of Trim24 knockout on HSCs:  
To determine if the HSC populations could 
be affected, fluorophore-conjugated antibodies 
were used to perform flow cytometry for the 
purpose of enumerating a population enriched for 
stem and progenitor cells, known as Lin-, Sca1+, 
Kit+ (LSK) cells.  As shown in figure 23, the bone 
marrow of Trim24 knockout mice (both in 12 week 
old and 6 month old mice) displayed no difference 
in LSK number when compared to wildtype mice 
from the same litter. 
  
Figure 23:  No difference in LSK number 
between Trim24 knockout and Trim24 wildtype 
healthy bone marrow. 
Figure 23 demonstrates no difference is observed 
for hematopoietic stem & progenitor cells (LSK) 
in the bone marrow of Trim24 wildtype and 
knockout mice. For both figure 23 a) and figure 23 
b), the y-axis represents the total number of LSKs 
in the tibia and femur bone marrow of mice.  The 
x-axis contains all categories measured in the 
experiment, which include Trim24 wildtype, 
Trim24 heterozygous, and Trim24 knockout mice. 
b) 
a) 
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Long-term competitive bone marrow reconstitution: 
To gather a more 
complete understanding of any 
putative effects Trim24 may 
have on normal hematopoiesis, 
we next performed a long-term 
bone marrow reconstitution 
(LTBMR) assay.  Examining 
hematopoietic populations in 
the context of a LTBMR assay 
provides not only a temporal 
aspect by repeatedly measuring 
peripheral blood populations at 
regular intervals, but is also 
fundamentally different than observing populations in the steady state, as the replicative stress 
forced upon small populations to completely reform the bone marrow can cause otherwise 
unobservable phenotypes to arise.  This assay provides great opportunities for observing biases 
towards cell maturation, but is also great for observing differences in self-renew capacity of HSCs.  
As shown in figure 24, the LTBMR assay revealed that mice reconstituted with Trim24 knockout 
bone marrow displayed 2/3 the ability to reconstitute the bone marrow when compared to 
wildtype.  An identical ratio was observed when comparing individual cell types.  While our 
measurements have some level of variability, this ratio did not change over the 18 week span of 
the experiment. 
  
Figure 24:  Trim24 knockout bone marrow shows mild reduction 
in reconstitution ability.
 
Figure 24 shows a roughly 2/3 difference in the ability of Trim24 
knockout (-/-) cells to reconstitute the bone marrow over a span of 18 
weeks.  The y-axis represents the percentage of CD45.2-positive cells 
observed per sample, which represents the reconstitution ability of 
each sample (see methods).  The x-axis represents weeks post-
injection of donor bone marrow following irradiation. 
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Discussion & Future Directions: 
Trim24 knockout AML in vitro: 
 Colony formation assays are frequently utilized as a method to gauge the stemness and 
self-renewal capacity of cell populations.   As is shown in figure 4, Trim24 knockout MLL-AF9 
AML cells have an increased ability to form colonies in vitro. This phenotype indicates that, in 
comparison to wild-type cells, the Trim24 knockout cell population has an increased number of 
stem-cell-like cells or an increased potential for self-renewal.  As AML is primarily driven by 
malignant stem cells, measurements of in vitro self-renewal capacity have marked implications 
for predicting a genotype’s effects on survival in an in vivo system.  Accordant with the increased 
number of colonies, Trim24 knockout leukemic cells also displayed an increased cell number per 
passage.  To further examine Trim24’s effects on self-renewal and differentiation in AML in vitro, 
Giemsa stains were performed on both the wildtype and knockout cells for the purpose of gauging 
levels of cell maturation present in each sample.  As can be seen in figure 6, Giemsa staining 
revealed no detectable difference in blast cell counts between either cell population, nor showed 
visually-distinguishable biases for any specific mature hematopoietic cell type.  Although the 
extent of cell maturation appears to be similar between the two genotypes, this alone is not 
contradictory to the colony formation data.  Phenotypic differences may lie within the rare 
leukemic initiating cell (LIC) population, which may not be readily observable upon broadly 
examining cell maturation through Giemsa staining.  
Trim24 knockout AML in vivo: 
The limitations of in vitro assays led us to conduct similar in vivo assays for the purpose of better 
comprehending TRIM24’s potential relevance in AML.  To this end, we performed primary 
leukemic transplants to assay the effect of Trim24’s presence in AML.  As shown in figure 7, no 
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significant survival difference was detected between wildtype and knockout groups; however, 
differences in survival frequently do not manifest themselves during the primary transplant.  
Often, phenotypic differences only evince themselves after serial transplantations, when the AML 
test groups are forced rely more heavily on LIC populations for sustained proliferation (86).  After 
performing and repeating secondary transplants, mice with Trim24 knockout AML displayed a 
marked decrease in survival (figure 8).   This significant survival difference exclusive to the 
secondary transplant connotes, in parallel with the colony formation data, a disparity in 
maintenance of LICs.  As with the in-vitro samples, we next measured broad levels of cell 
maturation through both Giemsa staining and Hemavet blood counts.  In both cases, no detectable 
differences were observed between either genotype, further supporting the notion that Trim24’s 
effects on AML may lie within the rare LIC population. 
As the data available from Trim24 knockout samples is characteristic of what would be 
observed from an increased self-renewal phenotype, we next enumerated the cell population 
postulated to be responsible - LICs.  As can be seen in figure 9, fluorescent antibody labelling and 
subsequent flow cytometry revealed that mice with Trim24 knockout AML displayed a 6-fold 
increase in LIC number.  The quiescent nature of LICs confers a resistance to conventional 
therapeutics, which solely target proliferative pathways (34, 87, 88).  Coupled with an elevated 
potential for self-renewal, LICs are widely accepted to possess the most potent effect on relapse 
and long-term survival of any known AML cell population (87, 88). 
A paradigm in LIC maintenance for MLL-fusion driven AML is dysregulation of the 
HOXA gene cluster, which plays a central role in regulation of hematopoietic self-renewal in both 
malignant and healthy tissue. To determine if this mechanism of action could potentially account 
for Trim24’s observed phenotypes, we performed qPCR on Trim24 knockout and wildtype 
samples to measure the extent to which presence of Trim24 affected expression of the key HOXA 
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cluster genes HOXA9 and MEIS1, both of which play roles in AML progression (89).  
Interestingly, in both leukemic bone marrow and in vitro samples, differences in the expression 
of neither were observed.  While not indicative of any particular mechanism, these data suggest 
that Trim24’s effect on the LIC population may be independent of HOXA cluster expression.  
More profoundly, this may indicate that Trim24’s effects on AML may be largely independent of 
MLL-direct targets (including the HOXA cluster); however, further experimentation is required 
to explore this possibility. A substantial portion of therapeutic strategies for MLL-fusion AML 
operate through targeting these pathways, giving our current results encouraging potential for 
original clinical applications.  The identification of a pathway novel with respect to AML LIC 
maintenance may illuminate previously unappreciated targets of clinical relevance, potentially 
opening up options for novel independent or combinatorial therapies. 
TRIM24 in AML TCGA data: 
Although experimentation in mice is generally an improvement over in vitro assays, 
limitations still exist.  One such limitation is that merely a small fraction of drugs relevant in mice 
move past phase III clinical trials.  To increase a study’s probability of maintaining relevance in 
human trials, obtaining the maximum amount of available data from human tissue is of paramount 
importance.  Accordingly, The Cancer Genome Atlas (TCGA) is a consortium involving 
participation from the NCI, NHGRI, and researchers from several hospitals, all aimed at 
comprehensively recording high-quality genomic information from human patients across 33 
different cancer types.  Along with recording next-gen sequencing data, an abundance of 
additional metrics were also recorded, enabling statistical association of mutation and expression 
data with patient characteristics.  Among the samples available in this database, tissue from 173 
adult AML patients had undergone both genomic and RNA sequencing. 
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We first used this information to search for associations between TRIM24 expression and 
both patient prognosis and mutation status.  This inspection revealed that high TRIM24 mRNA 
expression correlated with both low risk molecular and cytogenetic markers (figure 11 a).  
Furthermore, mutation rate was not correlated with TRIM24 mRNA expression (figure 11 b), 
suggesting TRIM24’s association with low risk prognosis markers is not an artifact arising from 
a lower mutation rate. Concordantly, a separate database holding a collection of leukemic and 
healthy hematopoietic microarray datasets (BloodSpot) demonstrated that TRIM24 expression is 
reduced in AML when compared to HSCs (figure 13).  This observation reinforces our hypothesis, 
as expression differences between HSCs and AML samples frequently represent alterations 
beneficial to leukemia.  To further investigate TRIM24’s relevance in human AML, we next 
obtained mRNA sequencing data from TCGA AML patients, and compared survival between 
patients above and below mean TRIM24 expression.  As can be seen in figure 14a, patients with 
high TRIM24 expression displayed a greatly increased survival, with a mean survival time 1.8 
times greater than patients with low TRIM24 expression.  With the collaboration of Yi Zhong (a 
senior statistical analyst for the department of Epigenetics & Molecular Carcinogenesis at MD 
Anderson), we next performed a more thorough survival analysis by removing arbitrary cut-offs 
such as “the mean” (see methods) (figure 15).  From this analysis, the survival difference remained 
strikingly prominent, yielding a p-value of 0.0007.  A caveat to this result is our observation that 
high TRIM24 expression is strongly associated with the M3 subclass of AML, which indisputably 
has the most favorable prognosis.  However, after excluding all M3 patients, TRIM24 expression 
still substantially correlated with survival (figure 14b), suggesting the observed survival trend is 
not merely an artifact of subtype-specific expression patterns.  While the number of AML patients 
in TCGA is insufficient to perform a comprehensive multivariate analysis, all three survival 
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analyses correspond with both our data and original hypothesis that loss of TRIM24 promotes the 
progression & aggressiveness of AML. 
In line with our murine AML LIC and blast percentage data, metrics recorded by TCGA 
also demonstrate that TRIM24 expression does not correlate with peripheral blood blast 
percentage, bone marrow blast percentage, platelet count, basophil count, nor white blood cell 
count (figure 16).  As with the in vitro and in vivo data, the lack of a correlation between TRIM24 
expression and visually enumerable cell populations suggests that the survival trend in human 
patients could potentially be the result of altered characteristics of the LIC pool. Also in-line with 
our in vitro and in vivo data, an examination of co-expression between TRIM24 and HOXA cluster 
genes in TCGA revealed no substantial association between the two (figure 17).  This is directly 
in-line with the hypothesis that TRIM24 is affecting survival through means other than canonical 
hematopoietic self-renewal pathways.  To further investigate the validity of this theory, we next 
examined the co-expression in TCGA between TRIM24 and a leukemic stem cell signature known 
for intensely correlating with patient survival, referred to as “Gentles leukemic stem cell up” in 
the Gene Ontology (GO) database (90).  In congruency with the HOXA cluster expression data, 
TRIM24 was not significantly correlated with the leukemic stem cell signature (Table 1). This 
result further supports the potentiality that the observed effects are a consequence of aberrations 
in a pathway novel with respect to AML progression. 
 To gather a more complete understanding of the pathways through which Trim24 could 
be affecting survival, we utilized co-expression data from TCGA to perform gene-enrichment 
analysis, yielding pathways enriched in both the top 1% of genes co-expressed with Trim24, and 
separately the top 1% of genes negatively co-expressed with Trim24.  While not excluding the 
possibility, this analysis did not indicate that loss of Trim24 is negatively affecting human survival 
through other common oncogenic pathways.  However, the gene enrichment analysis did reveal 
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that many immune-related pathways were associated with low TRIM24 expression.  While these 
immune regulatory pathways have no reported roles in AML, a re-examination of TCGA AML 
survival data revealed that one in particular, the leukocyte activation signature, negatively 
correlated with patient survival to a statistically significant extent (figure 18).  Our collaborator, 
Yi Zhong, independently validated the signature’s association with survival through ranked 
survival analysis utilizing an optimized cut-off (see methods). 
A caveat worth mentioning is the observation that low TRIM24 expression is associated 
with the M4 and M5 subclasses of AML (figure 12), both of which exhibit mature leukocytic 
features and poor survival.  To evaluate this association as a potential artifact explaining the 
observed signature and corresponding survival, a separate gene enrichment analysis was 
performed exclusively on M4 and M5 patients. Consequently, the analysis revealed that TRIM24 
expression still negatively correlated with leukocyte activation, suggesting TRIM24’s association 
with the pathway is not merely an artifact of subtype-specific expression patterns. 
In an effort to formulate a more complete picture of TRIM24’s participation in human 
malignancy, a broad examination of TRIM24 expression among all TCGA data sets revealed that 
low TRIM24 expression also correlated with poor survival in thyoma patients.  Like the correlation 
of TRIM24 expression and survival in AML patients, this observation is also unreported in the 
literature.  Perhaps more relevant to our hypothesis, however, is the observation that the leukocyte 
activation signature was also found to be negatively associated with TRIM24 expression in 
thyoma. This observation strongly bolsters the potential biological legitimacy of the statistical 
association between TRIM24 and leukocyte activation in AML, as such a highly similar statistical 
anomaly occurring in two separate TCGA datasets is unlikely.  These data, in combination with 
both previous reports of TRIM24 expression associating with favorable bone marrow status in 
ALL and our concordant experimental results, strengthen the legitimacy of TRIM24’s statistical 
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association with survival in AML.  This information altogether suggests that leukocyte activation 
may be the non-canonical pathway through which TRIM24 expression exerts its observed effect 
on LICs in mice, and could potentially be the underlying reason why TRIM24 expression 
correlates with survival in human patients. 
The apparent biological connection between TRIM24 and leukocyte activation should be, 
perhaps, unsurprising when examined in the context of the known role TRIM family members 
play in immunity.  A number of TRIM family members have been demonstrated to participate in 
the regulation of interferon signaling, repression of retroviral elements, and cytokine transcript 
production (58, 59).  These relationships provide rationale for TRIM24’s effect on AML LICs, 
when examined in the context of the HSC niche.  The HSC niche is, in part, regulated by cytokines 
produced by surrounding immune cells, such as the production of IL-3 and GM-CSF by T-cells 
to support maintenance of HSCs (91-95).  Correspondingly, genes comprising the “leukocyte 
activation” signature include several cytokines, as well as genes involved in their production and 
subsequent secretion.  While many aspects of HSC maintenance are disrupted through aberrant 
regulation in AML, many of the same components affect the regulation of LICs(94, 96, 97).  
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While mechanistic studies are required to provide the information needed formulate a 
robust model, our current hypothesis is that TRIM24 is indeed affecting AML leukemogenesis 
and progression by manipulating the expression of genes involved in the aforementioned 
“Leukocyte Activation” signature.  More specifically, we hypothesize that loss of TRIM24 
expression alters the cytokine milieu in a cell-autonomous manner to support leukemic 
progression.  In this hypothetical model (graphically described in figure 25), TRIM24 represses a 
multitude of elements involved in immune regulation, including a collection of cytokines.  Upon 
ablation of TRIM24 expression, these cytokines, which partly comprise the leukocyte activation 
signature, become overexpressed in AML cells.  Consequently, leukemic cells directly disrupt 
components of niche maintenance (such as IL-3 and GM-CSF signaling) and enforce positive-
regulation of LIC niche characteristics that hinder patient survival.  Although existing evidence 
is currently at an extremely preliminary stage, this hypothetical model outlines the rationale for 
further investigation of the relationship between TRIM24 and leukocyte activation in AML.  
Figure 25:   Current hypothesis from data available 
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TRIM24 in normal hematopoiesis: 
With evidence suggesting a role for TRIM24 in the regulation of LICs, we postulated that 
TRIM24 may too regulate normal hematopoiesis in a similar fashion. While the literature 
describes roles for TRIM24 in affecting immune cell expression, no reports to-date demonstrate a 
role for TRIM24 in hematopoietic maintenance or maturation.  Upon re-examining the BloodSpot 
datasets with particular focus on healthy hematopoietic cells, we observed that TRIM24 
expression is highest in HSCs and decreases with cell maturation, being lowest in myelocytes and 
monocytes.  If TRIM24 indeed negatively regulates leukocyte activation, this decrease in 
expression would be expected, so as to allow for the fulfillment of normal immune cell functions 
in mature hematopoietic cell types. 
 Paralleling our leukemic data, Giemsa staining of healthy Trim24 knockout bone marrow 
and blood revealed no significant difference in cell maturation levels.  Furthermore, a more 
intensive analysis of cell maturation was performed by utilizing flow cytometry to enumerate 
various hematopoietic lineages in the blood, spleen, and bone marrow, the results of which also 
failed to show any distinguishable difference between the two genotypes. Although no differences 
in cell number were observed, we sought to also directly enumerate the HSC populations of each 
genotype.  To this end, long-term and short-term HSC populations were enumerated by once again 
performing flow cytometry analysis; however, after several repetitions, the results indicated no 
detectable difference between the two genotypes (figure  23).  While these results are unsupportive 
of the hypothesis, differences in the ability to maintain a self-renewing stem cell population do 
not always manifest themselves from merely observing blood or bone marrow cell populations in 
the steady-state. The gold standard within this field for simultaneously comparing both self-
renewal capacity and differentiation biases between two genotypes is the long-term competitive 
bone marrow reconstitution assay.  This assay enables the comparison of each genotype’s ability 
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to completely reconstitute the bone marrow and blood of lethally irradiated mice.  By utilizing a 
variety of flow-cytometry antibodies, the extent to which each hematopoietic lineage is 
reconstituted can be individually measured.  After recording the ratio of wild-type and Trim24 
knockout cell populations in the blood at 2-week intervals for 18 weeks, we sacrificed the mice 
and measured hematopoietic cell populations in the spleen and bone marrow.  In all cases, the 
staining revealed no apparent bias for Trim24 knockout cells to produce any specific cell-type.  In 
contrast, a 2:3 ratio of total reconstitution ability was observed between Trim24 knockout and 
wildtype samples (figure 24); however, while statistically significant, this difference in magnitude 
is mild. Repetition of this assay is needed to verify its results, as the observed discrepancy could 
merely be an artifact of improper sample preparation or test conditions.  In line with this statement, 
a separate study reported no reconstitution advantage for Trim24 knockout or wildtype bone 
marrow (98).  Taken together, these data do not support our hypothesis that TRIM24 plays an 
important role in normal hematopoiesis.  
Future directions: 
Before the commencement of further testing, we need to further optimize our in vivo 
protocols.  In several attempts to repeat the primary leukemic transplants, Trim24 wildtype 
leukemic bone marrow failed to engraft in immune-compromised mice.  While the repeated 
successful engraftment of Trim24 knockout leukemic bone marrow itself touts support of our 
hypothesis for Trim24’s role in leukemic progression, widespread results from the field 
demonstrate no issues with the engraftment of control cells.  Without the development of leukemia 
within the control group, we cannot be certain all aspects of the protocol are being repeatedly 
properly.  This issue must be addressed to not only provide repeats to enable clear statistical 
assessment of our observed data, but also to ensure no unforeseen confounding factors generate 
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artifacts within the data.  Upon resolving this issue, further in vivo testing, such as additional 
survival analyses and measurement of cytokine levels, can progress. 
To further evaluate the legitimacy of our gene enrichment analyses from TCGA data, we 
aim to use next-generation sequencing methods such as RNA-sequencing (RNA-seq) and 
chromatin immunoprecipitation sequencing (ChIP-seq) for the purpose of assessing the 
participation of pathways and individual genes through which Trim24 could be exerting its effects 
in mice.  Unlike the human TCGA data, testing a single sub-type of AML in highly inbred mouse 
strains removes the need for complex multivariate analyses.  Furthermore, the capability of 
performing ChIP-seq in parallel with RNA-seq would enable for the cross-referencing of the 
resulting datasets, vastly limiting the potential regulators through which Trim24 directly exerts its 
effects.   
Beyond TRIM24’s effects on gene expression, the protein’s nuclear receptor interactions 
or E3 ubiquitin ligase activity could be responsible for our observed phenotypes. To address these 
possibilities, we intend to repeat our in vivo experiments with mice harboring non-synonymous 
mutations in the LXXLL motif of Trim24 (responsible for nuclear receptor interactions). This 
assay should partly reveal the extent to which TRIM24’s direct interaction with nuclear receptors 
effects TRIM24’s observed phenotypes in AML. In order to narrow down which receptor/s may 
depend on TRIM24 for nominal signaling in AML, monitoring the output of various nuclear 
receptors (with a key focus on retinoic acid receptor) should be experimentally assayed through 
qPCR of key targets for each receptor.  Expanding on this assay by performing a non-biased 
method such as immunoprecipitation followed by mass spectrometry could yield a more complete 
understanding about the TRIM24 interactome, further guiding mechanistic investigations of 
TRIM24 in AML. Although we do not anticipate TRIM24’s observed tumor suppressive activity 
in AML to be the result of P53 ubiquitination & degradation, we do expect that studying 
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TRIM24’s RING domain in AML will provide useful insights into the mechanisms of action of 
Trim24 in AML. To this end, the E3 ubiquitin ligase activity of TRIM24 could also be responsible 
for many of the aforementioned phenotypes, potentially through targeting proteins other than P53.  
For this reason, assessing the effects of catalytically dead TRIM24 in an in vivo AML mouse 
model should yield valuable information relevant to the potential mechanisms and intermediary 
effectors through which TRIM24 exerts its observed phenotypes. 
Recent information from Dr. James Bradner’s group has shed light on potential roles 
TRIM24’s E3 ligase activity (RING domain) may play in AML (99).  The group utilized a 
CRISPR-Scanning strategy to introduce mutations throughout the TRIM24 locus in various acute 
leukemic cell lines, and determine which mutations were detrimental to the cell lines’ progression.  
The results indicated that the cell lines examined (including the MLL-AF9 expressing AML cell 
line, MOLM13) were dependent on an intact TRIM24 RING domain.  While this information 
may at first appear contrary to the data presented in our study, TRIM24 may play a balancing act 
in AML, which could account for the information presented in both studies.  Similar to the fine 
balancing act TRIM24 plays in hepatocellular carcinoma, overexpression and underexpression of 
TRIM24 in AML could both have oncogenic consequences, albeit through different pathways.  
The stark difference in survival times between high and low expressing TRIM24 patients may 
simply result from the varying molecular paths each group may take to achieve oncogenesis, 
potentially by leading to dissimilarities in disease progression or response to treatment. 
This rationale leads to predictions for mutation patterns in AML.  For example, if a subset 
of patients maintain high TRIM24 expression for the oncogenic purpose of down-regulating P53, 
fewer TP53 mutations should be observed, as the redundancy of such mutations will not aid the 
selection of an evolving malignancy.  Conversely, low-expressing TRIM24 patients would be 
expected to have a higher frequency of TP53 mutations, as that would rescue the ability to reduce 
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P53 function lost with TRIM24 expression.  In accordance with this rationale, upon examining 
TP53 mutations among TCGA AML patients, we indeed observe this trend, with 11 out of 13 
TP53 mutant patients displaying TRIM24 expression below the mean.  However, a sample size of 
only 13 TP53 mutations is simply too small to give any statistical weight to this observation (p-
value = 0.11).  A larger sample size of mRNA expression and patient mutation data would be 
required to obtain the number of TP53 mutants requisite for such an analysis.  While this 
information is lightly supportive of TRIM24 playing a balancing act in AML, a genome-wide 
mutation analysis in the context of TRIM24 expression could provide further insight into which 
molecular landscapes coordinate with varying levels of TRIM24 expression. 
While current data does not support a role for TRIM24 in normal hematopoiesis, a role 
may yet exist in a separate hematopoietic context.  Given TRIM24 theorized role in leukocyte 
activation, examining hematopoiesis within the context of chronic infection may yield differences 
in hematopoietic ability between TRIM24 knockout and wildtype cells.  Additionally, assaying 
the extent of leukocyte activation in TRIM24 knockout and wildtype immune cells may yield 
insight into novel aspects of immunology.  
Summary / Conclusion:  
Overall, the cumulative data collected in this study supports our hypothesis that loss of 
TRIM24 promotes the progression & aggressiveness of AML.  While our data did not support the 
hypothesis that TRIM24 plays an important role in normal hematopoiesis, this result is exciting 
when viewed within the context of clinical relevance.  The lack of an apparent role for TRIM24 
in normal hematopoiesis suggests that AML therapies targeting the involved pathways may result 
in fewer negative side effects, potentially enabling a higher dosage and greater anti-leukemic 
effect than conventional treatments.  Furthermore, our results lead us to hypothesize that 
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TRIM24’s associations with survival are the result of a negative association between the 
expression of leukocyte activation and TRIM24.  From the available data, we also theorize that 
this signature’s correlation with poor prognoses is the result of altered regulation of leukemic 
initiating cells.  Regardless of the true presence, or lack thereof, of a relationship between 
leukocyte activation and TRIM24 expression, studying both in the context of AML progression 
will likely be a rewarding endeavor for providing a more comprehensive understanding of 
leukemogenesis and development of therapeutics.  Ultimately, this study succeeded in providing 
a framework for guiding the continued research of TRIM24 in AML. 
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Materials & Methods: 
Cell culture: Unless otherwise specified, all cells in this study were cultured in RPMI 1640 with 
2mm glutamine, cultured at 5% CO2, 37 degrees in Corning Falcon® 10 cm dishes (REF 353003).  
All cell counts were performed by first spinning down harvested cells at 1500 RPM for 5 minutes 
at 4 degrees, and subsequently resuspending in PBS.  10 ul of this solution was then mixed with 
10 ul of AOPI (Acridine orange & propidium iodide) stain and loaded onto a slide.  Cells on the 
slide where then counted by a Cellometer® K2 machine. 
Colony formation:  All colony formation assays were performed with StemCell™ Methocult™ 
M3234 semisolid media (Cat# 03234), supplemented with 5 ng/ul IL-3, 5ng/ul, IL-6, 100 ng/ul 
SCF, and pen-strep antibiotic.  Cultures were seeded with 5,000 cells in 2 mL Methocult in 
Corning Costar® 6-well plate (REF 3506).  Plates were left in incubator with 5% CO2 at 37 degrees 
for 10 days, at which point all plates were imaged with a Nexcelom Bioscience Celigo®-S to a 
resolution of 2 um per pixel.  The resulting images were used to count colony types manually. 
Storage of Cells:  All cells were stored in freezing medium consisting of 90% FBS and 10% 
DMSO.  Cells were harvested from cultures, washed in PBS, spun down at 1500 RPM for 5 
minutes at 4 degrees, and subsequently re-suspended in freezing medium to a density of 4 x 106 
cells per milliliter.  The resulting suspensions were then aliquoted into Corning 2 mL cryovials 
(REF 430488), with 1.5 mL in each vial.  The cryo-vials were next placed in a Nalgene cryo 
freezing container (Cat# 5100-0001), insulated with isopropanol, and placed in a -80 degree 
freezer.  After allowing to freeze overnight, all vials were next transferred to boxes stored in liquid 
nitrogen. 
qPCR:  All RNA analyzed was harvested by following the TRIzol® protocol for harvesting RNA 
from suspension cells.  Subsequently, cDNA copies of RNA were made by following the Bio-
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Rad iScript™ Reverse Transcription Supermix protocol for generating cDNA.  Per each well in 
our qPCRs, reaction mixtures were comprised of 5 ul SYBR Green master mix, 1ul forward 
primer, 1ul Reverse primer, 1 ul from 1:10 diluted cDNA stock, and 1 ul of DEPC water.  The 
working stocks for each primer were 10 uM.  All qPCRs were performed on a 7500 Fast Real-
Time PCR System from Applied Biosystems.  The machine was set to expose the sample to 95C 
for 5 minutes, then 40 cycles of 95C for 15s, 60C for 30s, and 72C for 30s.  One final cycle was 
performed of 95C for 15s, 60C for 60s, 95C for 30s (during which melt curves were generated), 
and 60C for 15s.  GAPDH was used as the reference gene for all qPCR experiments.  All primers 
can be found in table 3. 
Table 3 – primer sequences used in this study 
 
Retroviral infection and bone marrow transformation : BOSC cells, previously frozen in 
freezing media, were thawed and allowed to recover for one passage in a Corning Falcon® 10 cm 
dish (REF 353003).  BOSC cells were recovered and grown in DMEM with 10% FBS and pen-
strep antibiotic.  In the afternoon, 0.4 x 106 cells were plated in each well of a Corning Costar® 6-
well plate (REF 3506) and allowed to grow overnight to approximately 70% confluence.  Per well 
of cells, 6 ul of DNA:XtremeGene-9 was mixed with 1.6 ug of MLL-AF9 plasmid, 1 ug of pCL-
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Eco plasmid, and 94 ul of Opti-MEM.  The reagents were mixed via pipette and allowed to 
incubate at room temperature for 15 minutes.  100 ul of the resulting mixture was added to each 
well of BOSC cells. 72 hours before transfection, donor mice were injected with 5-fluorouracil 
for the purpose of killing proliferating cells, and thus enriching donor bone marrow for 
hematopoietic stem and progenitor cells. 
24 hours post-transfection, bone marrow from 8 – 12 week old mice was harvested, and plated in 
Corning Cellgro® DMEM (REF 10-013-CV) with 4ml per well and 2.5 million cells per well.  
5ng / mL IL3, 5ng / mL IL6, and 100ng / mL SCF were added to the media, and cells were allowed 
to incubate at 37C for roughly 24 hours, to stimulate cell division. 
48 hours post-transfection, BOSC culture supernatant (containing retrovirus) was harvested, and 
replaced with 2 mL of fresh DMEM.  Viral supernatant was supplemented with the same mixture 
of cytokines described above, with the addition of 4ug / mL polybrene.  Viral supernatant was 
then distributed equally among donor bone marrow cultures, which were subsequently spun at 
2500 rpm for 90 minutes at 25C, then placed back in the incubator. 72 hours post-transfection, 
the collection and spinning of viral supernatant was repeated.  The BOSC cells were harvested 
and run through flow cytometry analysis to determine transfection efficiency by measuring the 
percentage of GFP positive cells. 
96 hours post-transfection, donor bone marrow cells were cultured in Corning Falcon® 10 cm 
dishes (REF 353003) with StemCell™ Methocult™ M3234 semisolid media (Cat# 03234), 
supplemented with 5 ng/ul IL-3, 5ng/ul, IL-6, 100 ng/ul SCF, and pen-strep antibiotic. 
1-week post-transfection, donor bone marrow cells were harvested, spun down at 1500 rpm for 5 
minutes at 4C, resuspended in 1mL of PBS, and placed on ice.  A small fraction of these cells 
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were run through flow-cytometry to determine infection efficiency by measuring the percentage 
of GFP positive cells.  
Primary leukemic transplant: To carry out primary leukemic transplants, NOD-SCID mice 8-
12 weeks of age were injected through the tail vail with 100,000 GFP+ donor bone marrow cells 
from the transformation protocol.  Mice were then monitored over the course of 100 days, and 
euthanized when displaying moribund leukemic symptoms, such as hunched posture, immobility, 
unkempt fur, short & rapid breathing, and closed or winced eyes.  Blood, bone marrow, and 
spleens were all harvested after sacrificing leukemic mice.  A leukemic diagnosis of each mouse 
was later confirmed by running bone marrow cells through flow cytometry to determine the 
percentage of GFP+ cells. 
Secondary leukemic transplant: Secondary transplants were performed by harvesting leukemic 
bone marrow from mice which succumbed to leukemia in the primary transplant experiment as 
follows:  the percentage of leukemic cells in the BM of primary recipients was determined by 
measuring the GFP percentage via flow cytometry.  Based on this percentage, 100,000 GFP+ cells 
were subsequently injected into NOD-SCID mice 8 – 12 weeks of age.  Mice were then monitored 
over the course of 100 days, and euthanized when displaying moribund leukemic symptoms.  
Blood, bone marrow, and spleens were all harvested after sacrificing leukemic mice. 
Tail vein injection: Injections were carried out by placing mice in a restrainer specifically 
designed for tail vein injection, which holds the body of the mouse in place while exposing the 
tail.  The tail was then warmed with a heat pad to induce vasodilation of the tail vein.  
Subsequently, a 28 gauge insulin needle was used to inject 200 ul of solution into mice.  Such 
solutions varied on the experiment being conducted, but included bone marrow, leukemic cells, 
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and 5-fluorouracil (5FU).  All 5FU injection solutions were prepared by mixing 5mg of 5FU with 
PBS for a final volume of 200 ul. 
Euthanasia:  In line with IACUC standards, mice were euthanized via CO2 exposure in home 
enclosures with a flow rate of 30% displacement (1.8 liters) per minute until 1 minute after mice 
stop breathing (typically 6 minutes for adult mice).  Our lab is approved to employ cervical 
dislocation or exsanguination as secondary euthanasia methods.  For most mice, the thoracic 
cavity was immediately opened and the heart subsequently severed to not only ensure 
exsanguination as a secondary euthanasia method, but also to enable for the collection of large 
blood samples. 
Harvesting of bone marrow: Immediately following euthanasia, mice were sprayed with 70% 
EtOH, and skin on the lower half of each animal was removed.  Without damaging the ilium, the 
hind quarters were severed above the femur and immediately placed in ice-cold PBS.  In a sterile 
hood, all muscle and ligaments were removed from the bone, and the femur and tibia were 
separated.  A small incision was made on each end of the bones, and then PBS was flushed through 
them with a 28 gauge syringe, collecting all of the flow-through in a 1.5 mL tube.  This process 
was repeated until visibly all bone marrow had been flushed from the bones.  The solution with 
bone marrow was then spun at 2000 RPM at 4 degrees for 5 minutes, washed with PBS, 
subsequently spun at the same speed and resuspended in the desired volume for immediate usage, 
or frozen in freezing medium for future use. 
Harvesting of spleen: Immediately following euthanasia, spleens were removed from the same 
mice from which bone marrow was harvested.  The spleens were removed by extending the 
incision in the thoracic cavity (a remnant from the euthanasia protocol) downwards to expose 
organs in the abdomen.  By gently moving intestines aside with forceps on the animal’s left side, 
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the spleen was subsequently removed by using surgical scissors to separate the spleen from 
surrounding connective tissue.  All spleens were immediately placed in ice cold PBS before future 
processing.  For experiments in which sectioning of the spleen is intended, we halved the spleen, 
storing one half in 10% neutral buffered formalin (pH 6.8 – 7.2).  The other half would then be 
forced through a 40 micrometer nylon cell strainer to separate the spleen into single cells.  These 
cells would be washed in PBS, and were used for flow cytometry experiments, with excess cells 
being frozen in freezing medium. 
Long-term competitive bone marrow reconstitution assay:  CD45.1 C57/BL6 mice obtained 
from Charles River were committed to be recipients for the bone marrow transplant, and were 
thus irradiated with a lethal dose of 950 rads prior to receiving donor bone marrow.  These mice 
were homozygous for the CD45.1 allele of CD45, so as to make any remnant cells distinguishable 
through flow cytometry from our test groups, which were homozygous for the CD45.2 allele.  
Donor bone marrow was harvested from Trim24 knockout mice, Trim24 wildtype mice, and 
CD45.1 homozygous C57/BL6.  Separately, Trim24 knockout and Trim24 wildtype bone marrow 
were mixed with bone marrow CD45.1 C57/BL6 mice to obtain a 50:50 ratio of CD45.1 and 
CD45.2 cells (1.5 x 106 from each group).  Both bone marrow mixtures (Trim24 knockout / 
CD45.1 and Trim24 wildtype / CD45.1) were injected into recipient mice, five for each group.  
Every 2 weeks for the span of 18 weeks, in each mouse the bone marrow reconstitution ability 
was measured by comparing the ability of Trim24 knockout and Trim24 wildtype cells to out-
compete CD45.1 wildtype cells.  The comparative ability of each genotype to reconstitute the 
blood is represented the ratio of CD45.1 and CD45.2 cells in each mouse, as measured by flow 
cytometry. 
Geimsa stains: 50,000 cells in 50ul were first loaded onto a Thermo Scientific Cytoslide™ (REF 
5991056) and subsequently adhered to the slide’s surface through a cytospin protocol (800 rpm 
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centrifugation for 5 minutes).  The resulting slides were placed in May-Grunwald stain for 7 
minutes, then lightly rinsed with water.  The slides were next placed in Giemsa stain, diluted 20-
fold with distilled water, for 20 minutes.  The slides were again lightly rinsed with water, and left 
face-up on a flat surface to air-dry.  Blast percentages were counted by manually examining each 
slide under a microscope. 
Harvesting Blood Post-mortem: After severing the heart, blood was allowed to pool in the 
bottom of the thoracic cavity for approximately 15 seconds.  The pooled blood was then collected 
with a 1 mL pipet, and immediately transferred to a BD Microtainer® tube containing a K2EDTA 
anti-coagulating solution (REF 365974).  Each vial was either manually shaken or left on a rocker 
before analysis. 
Harvesting Blood from Live Mice: All blood from live mice was collected by puncturing the 
facial vein with a 4mm lancet.  8 droplets of blood (approximately 100 – 200 ul) were collected 
from each mouse, directly in a BD Microtainer® tube containing a K2EDTA anti-coagulating 
solution (REF 365974).  Each vial was either manually shaken or left on a rocker before analysis. 
Blood Counts: Blood collection tubes were placed into the HemaVet® hemacytometer, which 
takes 20 ul of blood from the sample and records numbers of leukocytes, neutrophils, 
lymphocytes, monocytes, eosinophils, basophils, erythrocytes, and thrombocytes. 
Processing of Peripheral Blood: Immediately after harvest, blood samples were brought up to 
10x the original volume with gibco® ACK lysis buffer (REF A10492-01).  Samples were 
incubated with the buffer for 15 minutes at room temperature, periodically rocking the tubes 
manually.  Each sample was then spun down at 2000 rpm at 4 degrees for 5 minutes, and all 
supernatant was removed.  Each pellet was then resuspended in an additional 1 mL of ACK lysis 
buffer, and incubated for an additional 10 minutes at room temperature.  Subsequently, 5 mL of 
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PBS was added to each sample and was then spun down at 2000 rpm at 4 degrees for 5 minutes, 
and all supernatant was removed. 
Flow Cytometry:  All flow cytometry was performed at the MD Anderson North Campus Flow 
Core.  After harvesting or thawing the desired cells and obtaining the desired cell concentration, 
all flow samples were incubated in a primary antibody solution (concentrations & combinations 
can be seen in table 4) for 1 hour in the dark on ice.  Each sample was subsequently spun at 1500 
rpm at 4 degrees for 5 minutes.  If a secondary antibody was required, it was instead resuspended 
in the secondary antibody solution and incubated for 1 hour in the dark on ice, otherwise each 
sample was resuspended in 300 ul of PBS with 2% FBS.  Each sample was then passed through 
a 35 um nylon cell strainer and moved to a Falcon® 5 mL round bottom tube on ice.   All samples 
and controls were then given to the core and run on a Gallios flow cytometer. 
Table 4 – antibody combinations & concentrations 
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TCGA data:  All TCGA data was downloaded through the cBioPortal, an online website 
dedicated to providing access to annotated TCGA results, as well as providing a query function 
to download data relevant to only genes of interest.  These data included sequencing data from 
200 adult AML patients, with 173 of these patients also having mRNA sequencing recorded.  
Metrics analyzed in this study include cell-type numbers, patient survival, patient prognosis, and 
patient classification, and expression of individual genes. 
TRIM24 mRNA association with quantitative patient metrics:  For each quantitative (non-
categorical) variable recorded by TCGA examined in this study, linear regression analysis was 
performed with TRIM24 mRNA expression, providing correlation coefficients and slopes of 
regression.  The p-values generated represent the statistical significance of the observed slopes 
being non-zero. 
TRIM24 mRNA survival analysis:  TRIM24’s correlation with overall survival in human AML 
patients from the TCGA database was calculated by first separating patients into two groups based 
on TRIM24 mRNA expression.  Patients with TRIM24 mRNA expression above the mean were 
defined as TRIM24 high expressing patients, and those expressing below mean expression were 
defined as TRIM24 low expressing patients.  Next, survival curves were generated for each group, 
the differences between which were statistically evaluated by utilizing a Log-rank (Mantel-Cox) 
test.  The same protocol was utilized when examining TRIM24’s association with survival in all 
other TCGA datasets. The same protocol was also followed upon evaluating TRIM24 survival in 
the absence of FAB M3 subtype patients (16 excluded in total).  The mean TRIM24 mRNA 
expression was re-calculated, and the survival between TRIM24 high and low expressing patients 
was re-evaluated. 
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Our collaborator Yi Zhong performed an independent survival analysis, in which arbitrary cutoffs 
(such as mean) were not used.  Instead, he utilized an optimized cutoff value, in which a program 
repeatedly performed multiple survival analyses to find a cutoff which associates with survival to 
the greatest magnitude.  The rationale behind this method is to provide a cut-off value which holds 
more biological relevance than any arbitrarily-chosen value.  This has the potential to provide 
more biologically relevant gene enrichment analyses by separating patients based on that same 
cut-off value. 
TRIM24 mRNA mutation analysis:  The top 12 most frequently mutated genes in TCGA AML 
patients (as determined by cBioPortal annotation of patient exome sequencing) were examined 
for mutation enrichment based on TRIM24 mRNA expression.  Mutation count for each gene 
among TRIM24 high and low expressing patients were tallied and compared, the numbers from 
which were statistically evaluated by utilizing Fisher’s exact test. 
TRIM24 mRNA association with cytogenetic risk:  TRIM24’s association with cytogenetic risk 
was evaluated by plotting TRIM24 mRNA expression for all patients within the 3 TCGA-
annotated cytogenetic risk groups, “Good”, “Intermediate”, and “Poor”.  The resulting 
information was analyzed statistically by performing a 1-way ANNOVA with Tukey’s multiple 
comparison test.  The multiple comparison test compared the mean of each group, to the mean of 
each remaining group individually, providing an adjusted p-value for the difference obtained in 
each comparison. 
TRIM24 by French-American-British (FAB) classification of AML:  The association of 
TRIM24 mRNA with AML FAB subtypes was examined by comparing the mean TRIM24 mRNA 
expression of each group, and subsequently performing a 1-way ANNOVA with Tukey’s multiple 
comparison test.  The multiple comparison test compared the mean of each group, to the mean of 
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each remaining group individually, providing an adjusted p-value for the difference obtained in 
each comparison. 
Gene enrichment analysis:  Preliminary gene enrichment analyses were performed by obtaining 
TRIM24 co-expression data for the entire genome, provided by cBioPortal.  From the genomic 
co-expression data, we formulated a list of the top 1% of genes in the genome co-expressed with 
TRIM24 mRNA, and a separate list of the top 1% of genes negatively co-expressed with TRIM24 
mRNA.  These lists were then separately run through online PANTHER software, which 
compares the number of genes in each GO-annotated pathway in your list, and evaluates the 
statistical difference of this number with the expected number of genes (under the assumption of 
random distribution).  The PANTHER software was chosen both for its ease of access, and recent 
update of GO pathways (updated monthly).  For all results, this protocol was performed unless 
otherwise specified. 
Our collaborator, Yi Zhong, independently performed a more intensive gene enrichment analysis.  
This involved utilizing an algorithm which provides a gene enrichment score for each GO 
pathway for each patient.  Next, a simply t-test was performed to determine if these gene 
enrichment values varied significantly between TRIM24 high and low groups, defined by the same 
cut-off obtained in Yi Zhong’s survival analysis. 
TRIM24 mRNA in normal hematopoietic cell types:  TRIM24’s association with specific 
hematopoietic cell types was evaluated by statistically analyzing the relationship between 
TRIM24 mRNA expression and corresponding cell type category.  These information were 
obtained through a database known as BloodSpot, which compiles microarray data from multiple 
studies, and uses an algorithm to provide batch corrections to all data, to make the data comparable 
between all studies in the database.  The statistical relationship between TRIM24 mRNA and cell 
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type was computed by performing a 1-way ANNOVA with Tukey’s multiple comparison test.  
The multiple comparison test compared the mean of each group, to the mean of each remaining 
group individually, providing an adjusted p-value for the difference obtained in each comparison. 
TRIM24 mRNA in AML and HSCs:  Differences in TRIM24 expression between 5 different 
AML subtypes and normal hematopoietic stem cells (HSCs) were statistically evaluated by 
performing a 1-way ANNOVA with Tukey’s multiple comparison test on the TRIM24 microarray 
data from each group.  The multiple comparison test compared the mean of each group, to the 
mean of each remaining group individually, providing an adjusted p-value for the difference 
obtained in each comparison.  The microarray mRNA data was obtained through a database 
known as BloodSpot, which compiles microarray data from multiple studies, and uses an 
algorithm to provide batch corrections to all data, to make the data comparable between all studies 
in the database. 
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